Formycon Reports Doubling of Revenue and Strategic Progress

Formycon AG has reported a significant increase in its nine-month revenue for 2026, doubling to €40 million compared to €19.5 million during the same period in 2025. This rise is attributed to milestone payments and commercialization revenues. The company's EBITDA improved notably, though it remains negative at €-8.9 million.

The FDA's acceptance of the Biologics License Application for Formycon’s FYB206, a pembrolizumab biosimilar, marks a significant milestone. This advancement highlights the company's strategic focus on its FYB4Growth initiative, expanding its pipeline with the new FYB286 development program.

Formycon anticipates continued growth despite the challenging market conditions affecting certain product returns. The firm's emphasis remains on biosimilars, which are gaining strategic importance for long-term growth despite recent impairments to existing product valuations.